Nexalin Technology, Inc. · NASDAQ:NXL
Nexalin Technology — Investor Presentation (March 2026)
32 slides from Nexalin Technology's investor presentation, March 2026
Slide 1: Harnessing the Power of Advanced Frequency Neurostimulation to Improve Mental Health
HARNESSING THE POWER OF ADVANCED FREQUENCY NEUROSTIMULATION TO IMPROVE MENTAL HEALTH INVESTOR PRESENTATION | MARCH 2026 NASDAQ: NXL
Slide 2: This presentation (this "Presentation") has been prepared by Nexalin Technology, Inc. ("Nexalin" or the
This presentation (this "Presentation") has been prepared by Nexalin Technology, Inc. (“Nexalin” or the “Company”) exclusively for informational purposes only, and is not, and may not be relied on in any manner as, legal, tax, regulatory, or investment advice, and shall not constitute an offer to se
Slide 3: Mental Health is a Global Epidemic
Mental Health is a Global Epidemic A Market full of Drugs, a Mind Full of Problems Alzheimer’s and Dementia2 Anxiety2 60M* Depression2 360M* 330M* s someone th ow a kn tn eed Everyone s help Insomnia1 TBI/PTSD (Military)2,3 850M* 350M* * Number of Patients INVESTOR PRESENTATION | MARCH 2026 3
Slide 4: Drugs & Therapy Are Big Business
Drugs & Therapy Are Big Business Market Opportunity: $60 Billion and Growing Alzheimer’s TBI/PTSD Insomnia4 Anxiety5 Depression6 and Dementia6 (Military) 7 PATIENT POPULATION 850M 360M 60M 330M 350M MARKET SIZE ($) $5B $ 12 B $5B $ 22 B $ 16 B • Low Efficacy DRUG 70% • Dangerous Side Effects Prefer
Slide 5: More Treatments that Don't Treat
More Treatments that Don’t Treat Current non-invasive neurostimulation technologies are marketed as alternatives to drugs but are limited by safety and efficacy: SAFETY EFFICACY Treatment response is Limited power = limited limited by patient’s efficacy (1-1.5 mA) threshold of discomfort Nexalin: 15
Slide 6: The Future of Mental Health Treatment is Here
The Future of Mental Health Treatment is Here Nexalin is replacing all current neurostimulator technologies with its new Deep Intracranial Frequency Stimulation (DIFS®). ✓ Undetectable to ✓ Increased power allows the human body for deeper penetration ✓ No patient discomfort ✓ Deeper penetration, or
Slide 7: Deep Intracranial Frequency Stimulation (DIFS)
Deep Intracranial Frequency Stimulation (DIFS®) Our DIFS device mirrors the brain’s natural energy rhythms to effectively reset and retrain networks associated with trauma. Nexalin’s undetectable Greater power = deeper proprietary waveform is penetration = greater response unique in shape, amplitude
Slide 8: Nexalin's Frequency Stimulation is not a Hypothesis
Nexalin’s Frequency Stimulation is not a Hypothesis Summary of clinical trials: Publications: ✓ 33 clinical trials ✓ 12 publications (available on the Nexalin website) ✓ 13 of these are International peer- reviewed clinical trials ✓ 3 recent articles published on the treatment of Alzheimer’s ✓ 7 of
Slide 9: Product and Strategy
PRODUCT AND STRATEGY INVESTOR PRESENTATION | MARCH 2026 9
Slide 10: From Proven Foundation to Next-Generation Neurostimulation
From Proven Foundation to Next-Generation Neurostimulation NEXALIN GEN 1* ✓ Waveform Technology In clinic solution 1-2 milliamp (mA), 77.5Hz frequency waveform for treatment without any discomfort or side effects ✓ Originally FDA cleared for anxiety, depression, and insomnia ✓ Cost Effective Lower p
Slide 11: Overall Growth Strategy
GEN 3 - HALO Remote Device OVERALL Enhanced access through GROWTH virtual clinic STRATEGY GEN 2 - SYNC Clinical Device Three regulatory pathways leading to commercialization More advanced, powerful ✓ Mood disorders – Anxiety, technology GEN 1 - FDA Depression, Insomnia Anxiety, Depression, Insomnia
Slide 12: Nexalin's Advanced Gen 2 - SYNC Technology
Nexalin’s Advanced Gen 2 - SYNC Technology Allows for deeper brain penetration and greater efficacy (clinically based) NEXALIN GEN 2 - SYNC ✓ Proprietary Waveform In clinic solution 15 milliamp (mA) waveform for deeper penetration. ✓ Increased Efficacy Proven effectiveness in mental health disorders
Slide 13: Bringing Advanced, Non-Invasive Treatment into the Home
Nexalin’s GEN 3 - HALO headset is coming… BRINGING ADVANCED, NON-INVASIVE TREATMENT INTO THE HOME 13
Slide 14: Nexalin's Gen 3 - HALO Device
Nexalin’s Gen 3 - HALO Device Allows patients to receive advanced neurostimulation treatment in their home with clinical supervision NEXALIN GEN 3 - HALO ✓ Same Increased Efficacy In home virtual clinic solution as Gen 2 – SYNC ✓ Convenient At Home Treatment through App and Virtual Clinic ✓ FDA Q-su
Slide 15: Physician Monitors Patient Compliance and Safety Through the Virtual Clinic
2 Patient self-administers treatment 5x per week for 4-6 weeks at home Provider uses software to access headset, assign protocol, and monitor patient compliance Provider prescribes the Physician Monitors Nexalin HALO through a 1 digital ecosystem known Patient Compliance as a virtual clinic and Safe
Slide 16: Nexalin Portfolio Poised For Rapid Commercial Growth
IN SUMMARY: Nexalin Portfolio Poised For Rapid Commercial Growth TBI/PTSD (Military) Alzheimer’s and DEPRESSION DEMENTIA INSOMNIA ANXIETY 2025 2026 2027 In Market (JV) INTERNATIONAL China, Brazil, Oman GEN 2 Pilot and Pivotal FDA SYNC Clinical Trials in USA USA Pilot and Pivotal Clinical I N T E R N
Slide 17: Market and Business Model
MARKET AND BUSINESS MODEL INVESTOR PRESENTATION | MARCH 2026 17
Slide 18: Go-to-Market Strategy
Go-to-Market Strategy Three Pathways Customers • Mood: • Clinicians and patients Anxiety | Depression | Insomnia (all pathways) • Military: TBI | PTSD • AD: Alzheimer’s Disease Delivery Model Product Strategy • Digital technology + digital • Gen 2 - SYNC: Sell device to treatment + digital distribut
Slide 19: National and International Regulatory Strategy
National and International Regulatory Strategy Nexalin is currently collaborating with FDA on clinical study design and strategy for De Novo clinical treatment application National: FDA applications (treatment, International breakthrough) filing strategy: • Current clearance with NMPA in Asia (China
Slide 20: Clinical Data / Sales Support - Mood Disorders
Clinical Data / Sales Support - Mood Disorders Insomnia / Depression: 75-90% of Patients Improve Insomnia Response Rate9 Depressive Disorder10 100% 94% 100% 77% Active Group Active Group Sham Group Sham Group 53% 54% 50% 50% 20% 17% 20% 18% 0% 0% End of Intervention 4-week Follow-up Week 8 CGI-I Wee
Slide 21: Sales Channel Support - Military
Sales Channel Support - Military Nexalin Military & TBI and PTSD Government Advisory Board Growing budgets and interest for military mental health services. Current emphasis is on treatment for traumatic brain injury and combat PTSD. General Wesley Clark NATO Supreme Allied Commander Congressman Don
Slide 22: Clinical Data / Sales Support - Alzheimer's and Dementia
Clinical Data / Sales Support - Alzheimer’s and Dementia Clinical Data Summary Cognitive Improvement Increased Brain Activity Stronger Communication and Memory Treated patients showed: Increased Regional Homogeneity values: • Cognitive improvements Treated group showed: (MMSE and MoCA) • Increased n
Slide 23: Global Growth Strategy
Global Growth Strategy Israel China USA Middle East South America $ 1B Global Market INVESTOR PRESENTATION | MARCH 2026 23
Slide 24: Intellectual Property
INTELLECTUAL PROPERTY Nexalin is developing a global intellectual property portfolio TACs Anxiety, Multi-Channel General Depression, Alzheimer’s General ✓ 7 Patents Issued, US – Electro- Electro- Stimulation TACs Insomnia and Dementia Stimulation through 2036 (ADI) ✓ 21 patents Pending across 14+ co
Slide 25: Nexalin Financials
NEXALIN FINANCIALS INVESTOR PRESENTATION | MARCH 2026 25
Slide 26: How Nexalin Makes Money
How Nexalin Makes Money The Nexalin business model is based on strong margins of device sales, recurring revenue, and subscription services. GEN 2 - SYNC GEN 3 - HALO IN CLINIC AT HOME Disclaimer: Price/unit $25-40K $3-5K Estimates based on Disposable Electrodes – Service subscription – Subscription
Slide 27: Nexalin Investment Summary
Nexalin Investment Summary US Trials on Gen 2 – SYNC and Gen New Innovative Gen 3 - HALO 3 – HALO expanding indications In-Home Virtual Clinic: across mental health spectrum strongest in market Proprietary, effective De Novo & safe non-invasive classification treatment option expected with in growin
Slide 28: Financial Snapshot as of December 31, 2025
Financial Snapshot as of December 31, 2025 $3.7M 23.6M Cash, Cash Equivalents, Fully Diluted Shares and Investment Including Options $0 0 Debt Warrants Outstanding (expired September 2025) 19.1M 17.73% Common Shares Management/ Outstanding Director Beneficial Ownership (per Form 10-K) INVESTOR PRESE
Slide 29: Harnessing the Power of Advanced Digital Neurostimulation to Improve Mental Health
HARNESSING THE POWER OF ADVANCED DIGITAL NEUROSTIMULATION TO IMPROVE MENTAL HEALTH Mark White NEXALIN President and Chief Executive Officer NASDAQ: NXL INVESTOR PRESENTATION | MARCH 2026 29
Slide 30: Nexalin Leadership
Nexalin Leadership Mark White Carolyn Shelton Justin Van Fleet President and Chief Executive Officer Chief Financial Officer Executive VP of Regulatory, Quality and Clinical Affairs • 20+ years experience in public • Leads Nexalin’s executive team accounting with deep expertise in and provides leade
Slide 31: Nexalin Leadership
Nexalin Leadership Reynold Yordy David Owens M.D. Zach Herrmann Chief Technology Officer Chief Medical Officer Chief Marketing Officer • 20+ years as a healthcare technology • 30+ years experience in • 15+ years in healthcare and executive and entrepreneur. neuroradiology and neuroimaging technology
Slide 32: Sources/References
Sources/References 1. Benjafield AV, Kuniyoshi FS, Malhotra A, et al. Estimation of the global prevalence and burden of insomnia: a systematic literature review-based analysis. Sleep Medicine Reviews. 2025;82:102121-102121. doi:https://doi.org/10.1016/j.smrv.2025.102121 2. World Health Organization
Nexalin Technology — Investor Presentation (March 2026) on 6ix